BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2018

View Archived Issues

AdAlta redesigns lead candidate for idiopathic pulmonary fibrosis

Read More

Biogen and Ionis expand strategic collaboration

Read More

IMPACT 1 and IMPACT 2 trial results lead to cadazolid's discontinuation

Read More

Clementia begins MO-Ped study of palovarotene

Read More

Merck & Co. patents novel mGlu2 receptor negative allosteric modulators

Read More

Vanderbilt University describes new WDR5/MLL1 interaction inhibitors

Read More

Novel CFTR modulators divulged by Vertex Pharmaceuticals

Read More

Sichuan Kelun-Biotech Biopharmaceutical discovers new FXR agonists

Read More

EMA grants orphan drug designation for ABO-202 gene therapy program in Batten disease

Read More

First efficacy and safety data presented from the RESTORE-IMI 1 phase III trial

Read More

Daiichi Sankyo discovers novel proto-oncogene tyrosine-protein kinase receptor Ret inhibitors

Read More

Novel calpain inhibitors identified at Blade Therapeutics

Read More

Patient enrollment ongoing in phase I study of ANX-007 in primary open-angle glaucoma

Read More

Primary endpoint not met in Arpeggio study of laquinimod in primary progressive multiple sclerosis

Read More

FDA approves intravenous Akynzeo

Read More

Farnesoid X receptor agonist EYP-001 safe and well tolerated in HBV-infected patients

Read More

New phase II trial explores GS-9131 functional monotherapy in HIV-1 patients failing NRTI regimen

Read More

Fujifilm studies FF-10832 in phase I trial for advanced solid tumors

Read More

Lilly reports further data from phase III RANGE study of Cyramza in advanced urothelial carcinoma

Read More

GlaxoSmithKline presents novel hSTING agonist GSK-532

Read More

FDA clears use of Bruker Maldi Biotyper CA system to identify C. auris

Read More

Novartis files for approval of tisagenlecleucel in Japan

Read More

Fresenius decides to terminate merger agreement with Akorn

Read More

TesoRx conducts pilot study of TSD-001 for low-grade stage Ta non-muscle invasive bladder cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing